Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
OnlineSemaglutide.org: Best for No-Frills, Transparent Pricing at $141/mo Best For: Anyone who wants straightforward access to compounded GLP-1s with flat pricing across all doses, no membership fees, and fast asynchronous approvals
Why what to eat on GLP-1s still matters First up, yes, GLP-1s can reduce cravings and appetite
Clinical trials have shown impressive results, with patients losing an average of 15-20% of their body weight when combined with lifestyle changes
Always follow your specific product's Patient Information Leaflet
You can see why in my full review of it here